Next Phase Newsletter

An early stage fund founded by a group of alumni from a leading university is based in the USA. The group currently has $100M, under management. The group focuses on Angel to Series B stage companies across various sectors, including pharmaceutical, medical device, services and tools, and digital health. The typical investment size is between $1M to $2M. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe.

The firm is currently looking for new opportunities in the life science space. The fund is opportunistic in terms of sectors, subsectors and indications. The fund typically invests in seed rounds and series A rounds. Historically, the fund has been active in life science companies developing innovative platform technologies and cross-disciplinary technologies.

The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One of the leading fully integrated biopharmaceutical companies in China has established three integrated R&D centers, with locations in USA and China. The firm has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes. The firm is actively seeking for licensing/collaboration on development candidates with first-in-class or best-in-class potentials, and commercial products with substantial market opportunities in China and worldwide.

The firm is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease, as well as a technology platform in Cell Therapy.

The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US, Europe or other countries, and intends to introduce the product to the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund in the process of raising USD 150 million will be used to invest in around ten to twelve early-stage startups. The fund will primarily look to participate in Series A fundraising but is open to earlier rounds as well. The firm will only participate in equity investments with an initial check size between USD 3 million and USD 7 million. The fund will primarily invest in companies that are based in the United States but is open to considering opportunities in Canada as well.

The firm is interested in investing in companies within the therapeutics, diagnostics, and medical technology sectors. The fund is modality agnostic and open to all companies within these sectors but will not consider investments in digital health. The firm will primarily seek to invest in therapeutics in the pre-clinical and Phase I stages of development as well as devices and diagnostics that are in development and clinical. The fund will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm prefers to work with experienced management teams that are made up of passionate and driven people developing great science. The fund is an active investor that will require a board seat and may act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital arm of a global generic manufacturer headquartered in Western Europe can invest up to $5m in a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital firm had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A thesis-driven earliest stage firm looks to lead investments in early-stage companies that are pre-seed. The firm is currently investing out of their second fund of USD 67 million. The firm primarily participates in equity investments including SAFEs but will consider other types of capital structures as requested by a founder. The firm invests largely in companies based in the United States and Canada but will also consider Europe and Latin America.

The firm is primarily interested in investing in companies in the digital health, diagnostics, and medical technology sectors with a focus in platform technologies. The firm will not consider investments in medical device companies. However, the firm will consider therapeutics with a platform technology component. The firm will only invest in technologies that are still pre-clinical and in development. The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm will work with experienced and inexperienced management teams. The firm looks to invest in founders who are dedicated to their technology and their company. The firm is an active investor and will take an observer board seat as determined on a case-by-case basis. The firm prefers to act as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office representing USA-based family interests is very flexible in terms of investment size, but are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. Currently, the firm is investing only in companies based in North America.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Currently, of particular interest are optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology and therapies correcting or treating loss of senses.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor. The firm is looking for companies that have already raised seed financing and have received allowance of claims by the USPTO.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.